Last reviewed · How we verify
Metronidazole, Cefuroxime
This combination uses metronidazole to disrupt bacterial DNA and cefuroxime to inhibit bacterial cell wall synthesis, together targeting anaerobic and aerobic pathogens.
This combination uses metronidazole to disrupt bacterial DNA and cefuroxime to inhibit bacterial cell wall synthesis, together targeting anaerobic and aerobic pathogens. Used for Mixed aerobic-anaerobic bacterial infections, Intra-abdominal infections, Gynecological infections.
At a glance
| Generic name | Metronidazole, Cefuroxime |
|---|---|
| Also known as | Zinacef 750mg (Cefuroxime 750mg, Glaxo Group Ltd., UK), Metronidazol 500mg (Metronidazole 500mg; B.Braun Melsungen AG, Germany) |
| Sponsor | The Faculty Hospital Na Bulovce |
| Drug class | Antibiotic combination (nitroimidazole + cephalosporin) |
| Target | Bacterial DNA (metronidazole); bacterial peptidoglycan/penicillin-binding proteins (cefuroxime) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Metronidazole is a nitroimidazole that generates reactive oxygen species in anaerobic bacteria, damaging their DNA and causing cell death. Cefuroxime is a second-generation cephalosporin that inhibits bacterial peptidoglycan cross-linking, weakening the cell wall. Together, they provide broad-spectrum coverage against both anaerobic and aerobic bacteria, commonly used in mixed infections.
Approved indications
- Mixed aerobic-anaerobic bacterial infections
- Intra-abdominal infections
- Gynecological infections
- Surgical site infections
Common side effects
- Nausea
- Diarrhea
- Metallic taste (metronidazole)
- Headache
- Allergic reaction (cephalosporin)
- Pseudomembranous colitis
Key clinical trials
- Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW) (PHASE4)
- Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis. (NA)
- Identification of the Optimal Treatment Strategy for Complex Appendicitis in the Pediatric Population
- Reducing the Incidence of Incisional Hernia After Stoma Closure Using a Prophylactic Mesh (NA)
- Role of Delay and Antibiotics on Perforation Rate While Waiting Appendectomy (PHASE4)
- The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial (NA)
- Bismuth Quadruple Therapy With Cefuroxime for Helicobacter Pylori Eradication Treatment (NA)
- Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metronidazole, Cefuroxime CI brief — competitive landscape report
- Metronidazole, Cefuroxime updates RSS · CI watch RSS
- The Faculty Hospital Na Bulovce portfolio CI